Folpan® Gold Česká republika - čeština - Adama

folpan® gold

adama - ve vodě dispergovatelné granule - folpet + metalaxyl-m - fungicidy

Bimervax Evropská unie - čeština - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcíny - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

RYKY MED A CITRON 2MG/0,6MG/1,2MG Pastilka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ryky med a citron 2mg/0,6mg/1,2mg pastilka

geiser pharma sl, mutilva array - 831 monohydrÁt lidokain-hydrochloridu; 83 amylmetakresol; 2163 2,4-dichlorbenzylalkohol - pastilka - 2mg/0,6mg/1,2mg - dichlorbenzylalkohol

ESCITALOPRAM VIATRIS 20MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

escitalopram viatris 20mg potahovaná tableta

viatris limited, dublin array - 16590 escitalopram-oxalÁt - potahovaná tableta - 20mg - escitalopram

FINASTERID VIATRIS 5MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

finasterid viatris 5mg potahovaná tableta

viatris limited, dublin array - 11225 finasterid - potahovaná tableta - 5mg - finasterid

LINATRA 5MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

linatra 5mg potahovaná tableta

zaklady farmaceutyczne polpharma sa, starogard gdański array - 18286 linagliptin - potahovaná tableta - 5mg - linagliptin

TANATRIL 5MG Tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

tanatril 5mg tableta

viatris healthcare limited, dublin array - 14186 imidapril-hydrochlorid - tableta - 5mg - imidapril

APIXABAN FARMAPROJECTS 2,5MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

apixaban farmaprojects 2,5mg potahovaná tableta

farmaprojects s.a.u., barcelona array - 17381 apixaban - potahovaná tableta - 2,5mg - apixaban

OSAGRAND 3MG Injekční roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

osagrand 3mg injekční roztok

zentiva, k.s., praha array - 14765 monohydrÁt natrium-ibandronÁtu - injekční roztok - 3mg - kyselina ibandronovÁ

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Evropská unie - čeština - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidla - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st elevace akutního infarktu myokardu, v kombinaci s asa u medikamentózně léčených pacientů vhodných pro trombolytickou terapii. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pro další informace viz bod 5.